Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

The Just MS (Multiple Sclerosis) Show

The Just MS (Multiple Sclerosis) Show artwork

Ocrevus: 10-Year Results, Myelin Repair Funding & MSToronto2026 | Just MS News

Oct 13, 202613 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail What can long-term treatment research tell us about living with MS - and what will it take to move myelin repair research forward? This week on Just MS News, Justin Loizos explores three stories connecting treatment, research funding and the MS community. OCREVUS: TEN-YEAR FINDINGS We examine the ten-year OPERA follow-up published in JAMA Neurology, what it suggests about starting ocrelizumab earlier in relapsing MS, and the limitations of interpreting long-term extension data. MYELIN REPAIR: THE FUNDING BEHIND THE RESEARCH Rewind Therapeutics has announced additional financing for its experimental oral GPR17 program. We revisit the mouse findings, explain why funding matters, and distinguish promising preclinical research from evidence that a treatment helps people. This announcement reports no new human treatment results. MSTORONTO2026: RESEARCH AND COMMUNITY The joint ACTRIMS-ECTRIMS meeting comes to Toronto October 21-23. We preview upcoming research, including planned remibrutinib results, and highlight Patient Community Day on October 23, with in-person and online participation. I’m excited about the opportunity and hoping I can attend. Disclosure: I have been taking Ocrevus for about four years and have worked with Roche on its co-creation council. SOURCES AND EVENT INFORMATION JAMA Neurology - Ten-year OPERA follow-up, Hauser and colleagues Rewind Therapeutics - October 6 financing announcement PLOS ONE - GPR17 preclinical study, De Herdt and colleagues Novartis - Upcoming MSToronto2026 presentations MSToronto2026 - Official conference website Patient Community Day - Information and registration What question would you most like MS researchers to answer? Share it in the comments, and subscribe for more Just MS News. Episode covering October 6-12, 2026. #MultipleSclerosis #MSNews #Ocrevus The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. When MS Isn’t MS, a New Tablet’s Trial Results & Earlier Clues Just MS News

    Nov 4, 202618 minAudio

    Send us Fan Mail Nearly 20 years with an MS diagnosis - then a different answer. An experimental MS tablet raises questions about effectiveness and safety. And researchers investigate whether AI could help recognize MS...

    Credit the people on this episode

  2. Christina Applegate’s MS Diagnosis Questions, Remibrutinib Results & CAR-T Safety | Just MS News

    Oct 27, 202618 minAudio

    Send us Fan Mail Description This week on Just MS News: Christina Applegate’s reported MS misdiagnosis, detailed Phase 3 results for remibrutinib, and early CAR-T findings that raise serious safety questions. Join...

    Credit the people on this episode

  3. New Clues to MS Damage, GLP-1 Drug Research & Progression Beyond Relapses | Just MS News

    Oct 20, 202617 minAudio

    Send us Fan Mail How can we better understand MS damage - and recognise progression when relapses aren’t happening? This week on Just MS News, Justin Loizos explores new research into MS damage, GLP-1 drugs and...

    Credit the people on this episode

  4. FDA Reviews Fenebrutinib, Remyelination Trial Begins & New MS Inflammation Target | Just MS News

    Oct 6, 202615 minAudio

    Send us Fan Mail This week in Just MS News, we cover three important developments across the MS research pipeline. The FDA has begun Priority Review of fenebrutinib for both relapsing MS and primary progressive MS,...

    Credit the people on this episode

  5. Alpha-Lipoic Acid Advances | EBV Before Relapse, Ocrevus & CAR-T - Just MS News

    Sep 22, 202616 minAudio

    Send us Fan Mail This week in Just MS News: Alpha-lipoic acid has passed an important interim checkpoint in the phase 3 OCTOPUS trial for progressive MS, while metformin will not continue. This does not yet prove ALA...

    Credit the people on this episode